Healio Selected as CancerX 2025 Accelerator Media Partner

Month 18, 2025

[Thorofare, NJ] March 2025 – Healio, a global information platform for healthcare professionals, is pleased to announce its partnership with CancerX, a public-private collaboration dedicated to the acceleration of innovation in cancer treatment. Healio has been selected as the official media partner for the CancerX 2025 Accelerator cohort, a group of innovative digital health and artificial intelligence startups focused on addressing critical challenges in oncology.

The CancerX Accelerator program connects unmet needs within Champion organizations with cutting-edge innovations from startups in the field. Startups within the Accelerator cohort may be championed by one or more organizations and receive a range of support, from mentorship and product feedback to conducting pilots and signing commercial agreements. The four-month program also provides a weekly curriculum that educates startups on working with health systems, industry, and the public sector and how to scale their business within oncology.

This year’s cohort will focus on advancing cancer care by improving access to treatment, accelerating clinical trials and providing personalized, connected care for patients beyond the clinic. Healio will highlight these breakthroughs and achievements through exclusive, in-depth interviews with the 2025 Accelerator cohort members and the four alumni groups from last year’s program.

“Healio is honored to be chosen as a Champion and serve as the CancerX Accelerator Media Partner. We’re excited to share the groundbreaking innovations created by the 2025 Accelerator Cohort with the wider oncology community,” said Joan-Marie Stiglich, ELS, Chief Content Officer, Healio.

Moffitt Cancer Center currently hosts CancerX. Thirteen entities have been selected as Accelerator Champions: Advocate Health, CEI Ventures, Dana Farber Cancer Institute, Elevance, Flare Capital Partners, Innsena, Johnson & Johnson, KidsX, MassChallenge, Memorial Sloan Kettering Cancer Center (MSK), Mercury, Oncology Ventures, and the Assistant Secretary of Technology Policy.

“We’re thrilled to welcome Healio as a media partner. With Healio’s extensive network of 2 million physicians, this partnership will provide invaluable exposure for the 14 startups in the Accelerator and enable seamless sharing of CancerX’s ecosystem and content with a broader healthcare audience,” said Kamal Jethwani, MD, MPH, Vice President, Digital Ventures, Moffitt Cancer Center.

CancerX has a proven track record of supporting startups that significantly impact the fight against cancer. This year’s final cohort includes: First Ascent Biomedical, We Are Here, Xploro, Fifth Eye, Encapsulate, Nen, Recursive Health, Gabbi, Dyania Health, AIQ Solutions, Manta Cares, Arcascope, Citrus Oncology, and mPATH Health.

To learn more about Healio’s platform and partnership opportunities, contact Joan-Marie Stiglich at [email protected].

###

About Healio
Healio is a multichannel information platform, providing health care specialists with tailored news, information and education in support of their daily practice of medicine. An in-depth, clinical information resource, Healio brings together award-winning news reporting with expert perspectives, dynamic video and multimedia, question-and-answer columns, CME and other custom educational activities, blogs, peer-reviewed journals and a wide range of popular medical book titles all in one place. For more information, visit Healio.com.

About CancerX
CancerX is a groundbreaking public-private partnership designed to accelerate innovation in the fight against cancer. Hosted by the Moffitt Cancer Center, in collaboration with the Office of the National Coordinator for Health Information Technology (ONC) and the Office of the Assistant Secretary for Health (OASH), CancerX is part of the InnovationX program launched in 2018.

###